Integra LifeSciences (NASDAQ:IART) Trading Down 3.7% – What’s Next?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares dropped 3.7% on Thursday . The stock traded as low as $15.53 and last traded at $15.46. 124,721 shares traded hands during trading, a decline of 86% from the average session volume of 873,826 shares. The stock had previously closed at $16.06.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Truist Financial increased their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Wells Fargo & Company raised their price target on Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. UBS Group started coverage on shares of Integra LifeSciences in a research report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price objective on the stock. Citigroup restated a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Finally, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Thursday, June 18th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $18.86.

Integra LifeSciences Stock Down 3.1%

The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -172.65, a price-to-earnings-growth ratio of 0.81 and a beta of 1.21. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. The firm has a 50 day moving average price of $17.48 and a two-hundred day moving average price of $14.71.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The firm had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities analysts expect that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Several large investors have recently modified their holdings of the business. Hsbc Holdings PLC bought a new position in shares of Integra LifeSciences during the fourth quarter valued at approximately $879,000. Paradigm Capital Management Inc. NY bought a new stake in shares of Integra LifeSciences in the 2nd quarter worth $61,766,000. UBS Group AG boosted its position in shares of Integra LifeSciences by 211.7% during the fourth quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock valued at $5,079,000 after buying an additional 277,745 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in shares of Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after acquiring an additional 211,774 shares during the last quarter. Finally, Walleye Capital LLC lifted its position in Integra LifeSciences by 202.0% during the first quarter. Walleye Capital LLC now owns 218,595 shares of the life sciences company’s stock valued at $2,059,000 after purchasing an additional 146,203 shares during the period. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery and wound care. Its technologies are designed to help healthcare professionals treat complex conditions, repair damaged tissue and support surgical procedures.

The company’s portfolio includes dural repair products and other neurosurgical implants, surgical instruments, regenerative tissue technologies, wound-care products and solutions for extremity reconstruction.